New targets and non-cytotoxics in ovarian cancer.

Suppr

超能文献

作者信息

Eisenhauer E A

机构信息

NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.

出版信息

Ann Oncol. 2006 Sep;17 Suppl 10:x247-50. doi: 10.1093/annonc/mdl268.

DOI:10.1093/annonc/mdl268

PMID:17018733

Abstract

摘要

相似文献

New targets and non-cytotoxics in ovarian cancer.

Ann Oncol. 2006 Sep;17 Suppl 10:x247-50. doi: 10.1093/annonc/mdl268.

Impact of new non-cytotoxics in the treatment of ovarian cancer.

Int J Gynecol Cancer. 2001;11 Suppl 1:68-72. doi: 10.1046/j.1525-1438.2001.11(suppl.1)sup1068.x.

Targeted therapy for epithelial ovarian cancer: current status and future prospects.

Int J Gynecol Cancer. 2003 Nov-Dec;13(6):701-34. doi: 10.1111/j.1525-1438.2003.13601.x.

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.

Expert Opin Investig Drugs. 2014 Jan;23(1):37-53. doi: 10.1517/13543784.2013.839657. Epub 2013 Oct 11.

Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

Int J Oncol. 2000 Mar;16(3):445-54. doi: 10.3892/ijo.16.3.445.

Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.

Cancer Metastasis Rev. 2006 Jun;25(2):243-52. doi: 10.1007/s10555-006-8504-6.

Pazopanib in ovarian cancer.

Expert Rev Anticancer Ther. 2015;15(9):995-1005. doi: 10.1586/14737140.2015.1081383. Epub 2015 Aug 20.

Ovarian cancer and antiangiogenic therapy: caveat emptor.

J Clin Oncol. 2014 Oct 20;32(30):3353-6. doi: 10.1200/JCO.2014.57.4574. Epub 2014 Sep 15.

Emerging growth factor receptor antagonists for ovarian cancer treatment.

Expert Opin Emerg Drugs. 2018 Mar;23(1):1-16. doi: 10.1080/14728214.2018.1446942. Epub 2018 Mar 12.

A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.

Gynecol Oncol. 2010 Mar;116(3):578-9. doi: 10.1016/j.ygyno.2009.10.068. Epub 2009 Nov 8.

引用本文的文献

PLoS Med. 2009 Feb 3;6(2):e24. doi: 10.1371/journal.pmed.1000024.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

New targets and non-cytotoxics in ovarian cancer.

Ann Oncol. 2006 Sep;17 Suppl 10:x247-50. doi: 10.1093/annonc/mdl268.

Impact of new non-cytotoxics in the treatment of ovarian cancer.

Int J Gynecol Cancer. 2001;11 Suppl 1:68-72. doi: 10.1046/j.1525-1438.2001.11(suppl.1)sup1068.x.

Targeted therapy for epithelial ovarian cancer: current status and future prospects.

Int J Gynecol Cancer. 2003 Nov-Dec;13(6):701-34. doi: 10.1111/j.1525-1438.2003.13601.x.

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.

Expert Opin Investig Drugs. 2014 Jan;23(1):37-53. doi: 10.1517/13543784.2013.839657. Epub 2013 Oct 11.

Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

Int J Oncol. 2000 Mar;16(3):445-54. doi: 10.3892/ijo.16.3.445.

Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.

Cancer Metastasis Rev. 2006 Jun;25(2):243-52. doi: 10.1007/s10555-006-8504-6.

Pazopanib in ovarian cancer.

Expert Rev Anticancer Ther. 2015;15(9):995-1005. doi: 10.1586/14737140.2015.1081383. Epub 2015 Aug 20.

Ovarian cancer and antiangiogenic therapy: caveat emptor.

J Clin Oncol. 2014 Oct 20;32(30):3353-6. doi: 10.1200/JCO.2014.57.4574. Epub 2014 Sep 15.

Emerging growth factor receptor antagonists for ovarian cancer treatment.

Expert Opin Emerg Drugs. 2018 Mar;23(1):1-16. doi: 10.1080/14728214.2018.1446942. Epub 2018 Mar 12.

A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.

Gynecol Oncol. 2010 Mar;116(3):578-9. doi: 10.1016/j.ygyno.2009.10.068. Epub 2009 Nov 8.

引用本文的文献

PLoS Med. 2009 Feb 3;6(2):e24. doi: 10.1371/journal.pmed.1000024.